Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jul 20, 2017
Durable CRs Continued After Recovery of Normal B Cells Anti-CD19 CAR T-cell Therapy Can Be Curative for Chemorefractory Aggressive NHL SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlight...
Jun 28, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the United States Patent and Trademark Office (USPTO) has provided a Notice of Intent to issue an Ex Parte Reexamination Certificate that confirms the patentability of amended claims pres...
Jun 27, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, has been named to MIT Technology Review's 2017 list of 50 Smartest Companies. To make the list, a company must exhibit technological leadership and business acumen which sets them apart from competitors. ...
Jun 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that management will present at two investor conferences in June 2017: Jefferies 2017 Global Healthcare ConferenceWednesday, June 71:30pm Eastern TimeNew...
Jun 5, 2017
Remissions Ongoing From 2.0 to Greater than 7.4 Months KTE-C19 Successfully Manufactured in Six Days Across a Range of Absolute Lymphocyte and Blast Counts Phase 2 Initiation Planned for 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- ...
May 26, 2017
First Investigational CAR-T Therapy to Demonstrate Positive Data in Aggressive Non-Hodgkin Lymphoma (NHL) Biologics License Application Submission Based on the Primary Analysis of the ZUMA-1 Phase 2 Trial Prescription Drug User Fee Act (PDUFA) Set for November 29, 2...
May 17, 2017
Clinical and Biomarker Correlates of Outcomes in ZUMA-1 Pivotal Trial of axicabtagene ciloleucel in Refractory, Aggressive Non-Hodgkin Lymphoma (NHL) Updated Efficacy and Safety Data from ZUMA-3, a Phase 1/2 study of KTE-C19 in Adult Patients with Relapsed/Refractory Acute Lymphoblasti...
May 8, 2017
Completed Submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Kite's CAR-T Therapy, Axicabtagene Ciloleucel, in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Initiated Two New Clinical Studies as Part of an Expanded KTE-C19 ...
May 1, 2017
Conference Call and Webcast Scheduled for 8:30 AM ET / 5:30 AM PT SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report first quarter 2017 financial results on Monday, May 8, 2017 prior to the open of U.S. based financial markets. The an...
Apr 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it won the Clinical Trial Result of the Year award for ZUMA-1, its pivotal CAR-T trial of axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma (NHL) at the Clinical and Research ...
Apr 4, 2017
Proprietary Linker and CD28 Costimulatory Domain for Polyfunctional T cell Activation without Tonic Signaling Phase 1 Clinical Study of KITE-585 in Patients with Multiple Myeloma Planned for 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma...
Apr 4, 2017
Proprietary Serum-Free Artificial Thymic Organoid (ATO) Reproduces T-Cell Differentiation in Human Thymus System Offers Technical Simplicity, Reproducibility, and Potential Scalability Kite Holds Exclusive License to the ATO Technology for the Development ...
Apr 2, 2017
44 Percent in Ongoing Response, Including 39 Percent in Complete Response (CR) with a Median Follow-up of 8.7 Months Median Duration of Response for CR Not Yet Reached Second Plenary Presentation Identified Biomarkers Associated with Response and Adverse Events ...
Mar 31, 2017
Kite is Preparing for Potential Approval and Launch for Axicabtagene Ciloleucel in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has completed the rolling submission with the U.S. Food and Drug Administration (FDA) o...
Mar 30, 2017
Plenary Presentation on Positive Primary Analysis of the ZUMA-1 Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma Plenary and Oral Presentations Highlighting Biomarkers and Product Characteristics Associated with Adverse Events and Objective Response in Patients with...
Page:
...
Next Last
 
= add release to Briefcase